| 1 | Administration of rituximab and methylprednisolone | Methylprednisolone | 7件: D00407D00407, D00751D00751, D00979D00979, D02994D02994, D05000D05000, D05001D05001, D05002D05002 💬 | MS4A12件: MS4A1, NR3C1 💬 | Hematopoietic cell lineage2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction | 0511件: 51 💬 | 
| 2 | Corticosteroid treatment (methylprednisolone or prednisolone) | Methylprednisolone | 14件: D00407D00407, D00472D00472, D00751D00751, D00979D00979, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0641件: 64 💬 | 
| 3 | Cyclophosphamide, azathioprine,prednisone,methylprednisolone | Azathioprine | 11件: D00238D00238, D00287D00287, D00407D00407, D00473D00473, D00751D00751, D00979D00979, D03033D03033, D05000D05000, D05001D05001, D05002D05002, D07760D07760 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0423件: 42, 43, 45 💬 | 
| 4 | Infliximab, methylprednisolone, methotrexate | Infliximab | 9件: D00142D00142, D00407D00407, D00751D00751, D00979D00979, D02115D02115, D02598D02598, D05000D05000, D05001D05001, D05002D05002 💬 | DHFR4件: DHFR, DHFR2, NR3C1, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications70件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Folate biosynthesis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Metabolic pathways, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, One carbon pool by folate, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 0461件: 46 💬 | 
| 5 | Interferon-beta-1a (avonex) plus methylprednisolone | Human interferon beta | 7件: D00407D00407, D00751D00751, D00979D00979, D04554D04554, D05000D05000, D05001D05001, D05002D05002 💬 | IFNAR13件: IFNAR1, IFNAR2, NR3C1 💬 | Coronavirus disease - COVID-1919件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway | 0131件: 13 💬 | 
| 6 | Intravenous (i.v.) methylprednisolone 1000 mg, total 9 | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 2221件: 222 💬 | 
| 7 | Intravenous methylprednisolone | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0132件: 13, 145 💬 | 
| 8 | Iv methylprednisolone | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0131件: 13 💬 | 
| 9 | Iv methylprednisolone (steroids) | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0131件: 13 💬 | 
| 10 | Megadose oral methylprednisolone | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0131件: 13 💬 | 
| 11 | Methotrexate + methylprednisolone | Methotrexate | 8件: D00142D00142, D00407D00407, D00751D00751, D00979D00979, D02115D02115, D05000D05000, D05001D05001, D05002D05002 💬 | DHFR3件: DHFR, DHFR2, NR3C1 💬 | Antifolate resistance6件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, Neuroactive ligand-receptor interaction, One carbon pool by folate | 0461件: 46 💬 | 
| 12 | Methylprednisolone | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 00244件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬 | 
| 13 | Methylprednisolone (drug) | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0131件: 13 💬 | 
| 14 | Methylprednisolone (mp) | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0602件: 60, 285 💬 | 
| 15 | Methylprednisolone (mp) or prednisone (pred) | Methylprednisolone | 7件: D00407D00407, D00473D00473, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0661件: 66 💬 | 
| 16 | Methylprednisolone (or other glucocorticoid) | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0431件: 43 💬 | 
| 17 | Methylprednisolone (solu-medrol) | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0141件: 14 💬 | 
| 18 | Methylprednisolone 1250 mg/24h x3 days | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0131件: 13 💬 | 
| 19 | Methylprednisolone acetate | Acetate | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0511件: 51 💬 | 
| 20 | Methylprednisolone bolus iv 15 mg/kg/d for 3 days. | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0841件: 84 💬 | 
| 21 | Methylprednisolone hemisuccinate | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0131件: 13 💬 | 
| 22 | Methylprednisolone iv | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0131件: 13 💬 | 
| 23 | Methylprednisolone mylan générique | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0661件: 66 💬 | 
| 24 | Methylprednisolone or budesonide | Budesonide | 7件: D00246D00246, D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0961件: 96 💬 | 
| 25 | Methylprednisolone or prednisolone | Methylprednisolone | 14件: D00407D00407, D00472D00472, D00751D00751, D00979D00979, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0651件: 65 💬 | 
| 26 | Methylprednisolone po | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0131件: 13 💬 | 
| 27 | Methylprednisolone pulse | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0662件: 66, 220 💬 | 
| 28 | Methylprednisolone sodium hemisuccinate | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0132件: 13, 97 💬 | 
| 29 | Methylprednisolone sodium succinate | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0136件: 13, 46, 49, 50, 51, 211 💬 | 
| 30 | Methylprednisolone(intravenously in the 1st-2nd-3rd month ) | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0661件: 66 💬 | 
| 31 | Methylprednisolone(intravenously in the 1st-3rd-5th month) | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0661件: 66 💬 | 
| 32 | Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone | Mesalazine | 7件: D00377D00377, D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0971件: 97 💬 | 
| 33 | Oral methylprednisolone 625 mg/24h x3 days | Methylprednisolone | 6件: D00407D00407, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0131件: 13 💬 | 
| 34 | Prednisone (and methylprednisolone) | Methylprednisolone | 7件: D00407D00407, D00473D00473, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0431件: 43 💬 | 
| 35 | Prednisone, methylprednisolone,cyclophosphamides | Methylprednisolone | 7件: D00407D00407, D00473D00473, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0423件: 42, 43, 45 💬 |